Fate Therapeutics (DE:F6T)
FRANKFURT:F6T
F6T Stock Chart & Stats
€1.00
€0.07(3.83%)
At close: 4:00 PM EST
€1.00
€0.07(3.83%)
Day’s Range― - ―
52-Week Range€0.65 - €1.49
Previous CloseN/A
Volume185.00
Average Volume (3M)0.00
Market Cap
€120.00M
Enterprise Value€169.57M
Total Cash (Recent Filing)€203.66M
Total Debt (Recent Filing)€77.85M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
May 06, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding116,263,460
10 Day Avg. Volume1
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)17.56
P/FCF Ratio-1.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.73Price Target Upside73.08% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.98
Revenue Forecast (FY)€5.06M
Bulls Say, Bears Say
Bulls Say
Clinical Trial EnrollmentEnrollment expansion across multiple international clinical sites increases the likelihood of achieving meaningful patient numbers and supports broader assessment of the therapy across different populations.
Regulatory DesignationA regulatory fast-track designation strengthens the pathway toward pivotal testing and facilitates more focused interactions with regulators for systemic autoimmune and kidney indications.
Treatment Delivery ScalabilitySuccessful outpatient administration without intensive conditioning could remove major logistical barriers and enable more scalable delivery beyond specialized inpatient centers.
Bears Say
Evidence RobustnessLimited clinical experience increases the chance of unforeseen safety issues or variable treatment responses as the program expands into broader patient groups.
Limited Patient DataThe program has treated only a small number of patients, which limits the strength of conclusions about safety and effectiveness until larger datasets are collected.
Safety And Efficacy UncertaintySparse patient exposure reduces statistical confidence in observed responses, raising the risk that early signals may not translate to consistent benefits in larger cohorts.
Fate Therapeutics News
F6T FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was €0.65 and its highest was €1.49 in the past 12 months.
What is Fate Therapeutics’s market cap?
Fate Therapeutics’s market cap is €120.00M.
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is May 06, 2026 which is in 28 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Feb 26, 2026. The company reported -€0.234 earnings per share for the quarter, the consensus estimate of -€0.234 by €0.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 116,263,460 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -€0.234 in its last earnings report, expectations of -€0.234. Following the earnings report the stock price went down -9.125%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Currently, no hedge funds are holding shares in DE:F6T
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€1.73 (73.08% Upside)
€1.73 (73.08% Upside)
Blogger Sentiment
Bullish
DE:F6T Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $16.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.44%
12-Months-Change
Fundamentals
Return on Equity
-55.02%
Trailing 12-Months
Asset Growth
-27.63%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
F6T Stock 12 Month Forecast
Average Price Target
€1.73
▲(73.08% Upside)
Technical Analysis
Options Prices
Currently, No data available
---